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ess: mobeireek@yahoo.Summary Obliterative bronchiolitis (OB) is known to result from many causes,
such as post-bone marrow transplantation, autoimmune and infectious causes, and
from drugs. We report a 16-year-old female patient who was diagnosed with
myelodysplastic syndrome (MDS) and referred for pulmonary evaluation prior to bone
marrow transplantation (BMT). Her chief complaints were progressive cough and
dysponea. Her radiological and pulmonary function tests were highly suggestive of
advanced OB, which was confirmed by a lung biopsy. She eventually died despite
steroid therapy. The possible aetiology of OB in this patient is discussed, but, to our
knowledge, this is the first case report of OB associated with MDS.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Obliterative bronchiolitis (OB) is characterized by
inflammation and obstruction of the bronchiolesElsevier Ltd. All rights reserv
427493;
com (A. Mobeireek).that results in progressive, often fatal, respiratory
failure. Many causes and associations have been
reported in relation to this syndrome, the com-
monest being after lung or bone marrow transplan-
tation (BMT).1 Herein, we report an unusual case of
a patient with myelodyplastic syndrome (MDS), who
developed OB whilst being evaluated for BMT. We
discuss the possible aetiology and pathogeneticed.
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association of these two syndromes has not been
previously reported.Case report
A 16-year-old female with MDS (WHO classification:
refractory anemia with multilineage dysplasia) was
referred for pulmonary evaluation prior to BMT. She
presented to a local hospital in January 2000 with
pancytopenia; and after preliminary investigations
was thought to have MDS. She also had intermittent
cough and dysponea, with occasional exacerbations
that were thought to be infective and were treated
with antibiotics. She was diagnosed to have
asthma, and bronchiectasis and was treated also
with bronchodilators and steroids. However, a
computed tomography scan (CT) of the chest
performed later, in June 2002, showed no bronch-
iectasis and no other abnormalities except for a
few scattered fibrotic scarring believed to be
related to previous infection. Pulmonary function
tests at that time (Table 1) showed moderate
combined restrictive and obstructive defects but no
reversibility test was performed. She had no other
health problems other than patent ductus arter-
iosus, which closed spontaneously.
Her chief complaints when she presented to our
pulmonary clinic in June 2003 were cough and
dysponea on mild to moderate exertion. She denied
fever, sputum production and haemoptysis. She was
receiving folic acid, and granulocyte or granulo-
cyte-macrophage colony stimulating factor (G/GM-
CSF) for infections or as prophylaxis since 2001. On
examination, the patient was in no apparent
respiratory distress. She was underweight
(31.5 kg, height 146 cm, BMI ¼ 14.8). Her vital signs
were within normal range. Oxygen saturation onTable 1 Pulmonary function tests of the patient.
Date
parameter
June 2002 March 2003 June 2003 (d
& steroids)
FVC 1.44 (60)y 0.87 (36) 0.82 (34)
FEV1 1.24 (60) 0.63 (31) 0.61 (30)
Ratio 86 (102) 73 (86) 75 (88)
RV 1.13 (132) 1.76 (205) 1.7 (203)
TLC 2.5 (74) 2.6 (78) 2.5 (76)
DLCO ND ND 69
ND: Not done.
Values are in litres except of DLCO where the percentage of p
yValues between parentheses indicate percentage of predictedroom air was 94%. Chest examination showed
bilateral rhonchi and inspiratory crackles. The
remainder of the examination was unremarkable.
Her investigations included the following: WBC
2.59 109/L, polymorphs 8%, lymphoctes 89%, Hb
91 g/L, platelets 53 109/L, urea 3.4mmol/L,
creatinine 68 mmol/L, protein 72 g/L, albumin
36 g/L, bilirubin 8 mmol/L, ALT 1669 IU/L, AST 470
IU/L, GGT 196 IU/L, but LDH and alkaline phos-
phatase were normal. Thyroid function was normal,
hepatitis A IgG antibody was reactive, but hepatitis
A, IgM, B and C, HIV1+2, HTLV 1+2, schistosoma,
toxoplasma, Epstein-Barr, herpes simplex, varicella
zoster and cytomegalovirus (CMV) antibodies were
all negative. Antinuclear, anti SSA, anti SSB, anti-
thyroglobulin, anti-mitochondrial, anti-smooth
muscle, anti-neutrophil antibodies, and rheuma-
toid factor were all negative. Bone marrow aspira-
tion and biopsy showed moderate hypercelluarity
with trilineage dysplasia; cytogenetics were nor-
mal. Tests for possible chimerism from previous
transfusions, including fluorescent in situ hybridi-
zation (FISH) for the X chromosome and short
tandem repeats (STR), were negative. Pulmonary
function tests are shown in Table 1.
High-resolution computed tomography scan
(HRCT) showed mosaic pattern suggestive of OB
(Fig. 1). Bronchoalveolar lavage (BAL) before
treatment showed a total WBC count of
355 106/L (76% polymorphs, 12 lymphocytes).
She also underwent thoracoscopic lung biopsy,
which confirmed the presence of OB (Fig. 2).
She was started on Prednisone 25mg daily as well
as inhaled steroid and bronchodilator (Seretides
250mcg twice per day). Over the following few
months, she showed progressive improvement in her
symptoms and PFT (Table 1). A repeat BAL 6 weeks
after the initial one showed significant change; WBC
counts was 353 106/L (polymorphs 3% and lympho-
cytes 20%). She was maintained on the same therapyiagnosis July 2003 August
2003
December
2003
1.01 (42) 1.17 (47) 1.04 (42)
0.7 (34) 0.81 (38) 0.69 (33)
69 (82) 69 (82) 66 (79)
1.58 (185) ND 1.6 (186)
2.6 (78) ND 2.8 (81)
67 77 ND
redicted values is stated.
values.
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Figure 1 An expiratory high-resolution computed tomo-
graphic scan (HRCT) showing widespread areas of
hyperlucency (darker areas), indicating air trapping, a
sign of bronchiolitis. The smaller areas that are hypolu-
cent represent the normal lung. The, faint scattered tiny
nodules are another direct sign of bronchiolitis.
Figure 2 High-power view of the lung biopsy of the
patient showing constrictive bronchiolitis with terminal
bronchioles that shows sub-mucosal fibrosis and chronic
inflammation, causing narrowing of their lumen (H & E).
Obliterative bronchiolitis and myelodysplasia 361with slow tapering of prednisone dosage. She
remained stable in terms of symptoms, exercise
capacity and lung function over the subsequent 6
months. Plans for BMT were abandoned because of
her poor pulmonary function. She then presented to
her local hospital with fulminant pulmonary infec-
tion and respiratory failure with pulmonary infil-
trates and died despite aggressive therapy.Discussion
A wide spectrum of pulmonary pathology has been
associated with MDS, including those that areinfection-related, interstitial pneumonia, lympho-
ma, amyloidosis, bronchiolitis obliterans organizing
pneumonia (BOOP), Sweet’s syndrome, etc.2–6 To
the best of our knowledge, this is the first report of
OB in association with MDS.
On the other hand, the wide range of etiologies
of OB, other than this unusual association with MDS,
is well known; common ones being post-transplan-
tation (lung, bone marrow), autoimmune, post-
infectious, toxins, inhalational injury, drugs and
others.1 The pathological pattern of OB, therefore,
although characteristic, is non-specific, as it
represents an injury resulting from a variety of
insults.1
The pathogenetic mechanisms of bronchiolitis
are not well understood, but it is believed that the
neutrophil is a key cell in the underlying inflam-
matory process. This cell produces superoxide
anions and proteases that, with the subsequent
repair process cause tissue damage.6,7 Neutrophilia
is a characteristic finding in the BAL of patients
with bronchiolitis, and responds to steroids,6,7 as
was the case in our patient. Factors causing
recruitment of neutrophils to the target site are
not fully understood, but may be due to several
chemokines such as IL-8 released by abnormal Tand
B-lymphocytes in the interstitium.5,7–9 The inflam-
matory process is probably similar to that of usual
interstitial pneumonia (UIP),7 or desquamative
interstitial pneumonia (DIP) that are associated
with MDS.8 The question remains, however, as to
why the injury was confined to the bronchioles in
our case and did not extend distally to the acinus as
in DIP associated with MDS. The pathogenesis of
MDS also involves the release of cytokines, includ-
ing tumor necrosis factor alpha, transforming
growth factor beta, and interlukin-1 beta. Whether
these cytokines or associated infections played a
role in the pathogenesis of OB in our patient
remains unclear.
GM-CSF is a cytokine that simulates hematopoi-
esis of granulocytes and monocytes as well as
activating these cells (enhancing free radical
production) and prolonging their survival.10 The
disturbance in cytokine regulation brings about
alterations in the molecular dynamics that play an
important role in respiratory diseases. These
alterations were observed experimentally in ani-
mals10 and in clinically in humans.9,11 Our patient
received multiple doses of G/GM-CSF. It is possible
that G/GM-CSF is have contributed in the under-
lying inflammatory process. Clinical reports of
G/GM-CSF-induced pulmonary disease include
adult respiratory distress syndrome (ARDS) and
interstitial pneumonitis,12 but no association with
OB has been reported before.
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as infections, toxins, inhalational injury, etc. were
excluded by history and appropriate investigations.
Infectious causes have been reported mainly in
transplant recipients of lung and bone marrow.
Pathogens associated with OB are almost exclu-
sively respiratory, and several are common causes
of respiratory tract infections in healthy indivi-
duals, with no long-term sequela. Such pathogens
range from influenza and parainfluenza viruses,
respiratory syncytial virus (RSV), adenovirus to
Chlamydia pneumoniae and CMV. Recent studies
have indicated significant association between CMV
infections and OB in lung and bone marrow
transplant recipients. A pulmonary infection is
unlikely as thorough investigation, including BAL
and serology, while her disease was actively
progressing, failed to identity any pathogens.
Finally, OB resulting from a graft versus host from
donor cells of previous transfusions is unlikely with
a negative STR tests. Investigations for etiology of
the associated hepatitis did not yield any specific
information, but it is likely to be related to the
process that resulted in the OB syndrome. Unfortu-
nately, she died without a liver biopsy and an
autopsy was not performed.
In conclusion, we believe that this is the first
documented, histologically proven case of OB in a
patient with MDS. Clinicians are alerted to consider
this syndrome and recognize it early in the course
of MDS, if the outcome is to be improved. Further
research is required to study the abnormal patho-
genetic mechanisms that lead to OB, including the
role of drugs such as G/GM-CSF, which would
hopefully lead to a more effective management
of this devastating disease.Acknowledgement
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